Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study-Reference-Cited by-同舟云学术

Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study

Published:2006-05 Issue: Volume:17 Page:iv18-iv24
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Corazzelli G.,Russo F.,Capobianco G.,Marcacci G.,Della Cioppa P.,Pinto A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/suppl_4/iv18/436381/mdj994.pdf

Reference26 articles.

1. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma;Fisher;N Engl J Med,1993

2. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation;Philip;Blood,1991

3. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma;van Besien;Blood,1998

4. Gemcitabine and its combinations in the treatment of malignant lymphoma;Chau;Clin Lymphoma,2002

5. The role of ifosfamide in the treatment of lymphomas;Hagemeister;Leuk Lymphoma,1999

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma;Cancer Immunology;2020

2. Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation;Leukemia & Lymphoma;2019-09-12

3. Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma;Terapevticheskii arkhiv;2019-07-15

4. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting;American Journal of Health-System Pharmacy;2018-05-01

5. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma;Biology of Blood and Marrow Transplantation;2016-10